Price
CHART BY
Frequently asked questions
What is Anavex Life's market capitalization?
The market capitalization of Anavex Life is $825.44M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Anavex Life?
Anavex Life's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.567. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Anavex Life's stock?
Currently, 2 analysts cover Anavex Life's stock, with a consensus target price of $44.00. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Anavex Life?
Anavex Life's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$54.90M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Anavex Life?
Anavex Life has a free cash flow of -$37.10M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Anavex Life have, and what sector and industry does it belong to?
Anavex Life employs approximately 42 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Anavex Life's shares?
The free float of Anavex Life is 82.98M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $825.44M
- EPS (TTM)
- -$0.567
- Free Float
- 82.98M
- EBITDA (TTM)
- -$54.90M
- Free Cashflow (TTM)
- -$37.10M
Pricing
- 1D span
- $9.487$10.37
- 52W span
- $5.03$14.43
Analyst Ratings
The price target is $44.00 and the stock is covered by 2 analysts.
Buy
2
Hold
0
Sell
0
Information
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
- Employees
- 42
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- AVXL
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet